indazoles has been researched along with vorinostat in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R | 1 |
| Archin, NM; Burch, BD; Margolis, DM; McManamy, ME; Tripathy, MK | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 1 |
| Broaddus, R; Fu, S; Hess, K; Hong, D; Janku, F; Karp, D; Kopetz, S; Liu, L; Naing, A; Overman, M; Piha-Paul, S; Shi, N; Subbiah, V; Tsimberidou, AM; Wang, Y; Yao, J | 1 |
| Jiang, W; Li, L; Liao, Y; Liu, Y; Luan, Y; Sun, D; Wang, Y; Xue, X; Zhang, J; Zhang, Y; Zhao, X | 1 |
1 review(s) available for indazoles and vorinostat
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
2 trial(s) available for indazoles and vorinostat
| Article | Year |
|---|---|
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasms; Neovascularization, Pathologic; Proportional Hazards Models; Protein Stability; Proteolysis; Pyrimidines; Sulfonamides; Texas; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2015 |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2020 |
3 other study(ies) available for indazoles and vorinostat
| Article | Year |
|---|---|
H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Topics: Analysis of Variance; CD4-Positive T-Lymphocytes; Chromatin Immunoprecipitation; Enhancer of Zeste Homolog 2 Protein; Enzyme-Linked Immunosorbent Assay; Histones; HIV; Humans; Hydroxamic Acids; Immunoblotting; Indazoles; Methylation; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Proviruses; Pyridones; RNA, Small Interfering; Vorinostat | 2015 |
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycine; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Vorinostat | 2016 |
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Design; Histone Deacetylase Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Indazoles; Mice; Microsomes, Liver; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Vascular Endothelial Growth Factors; Vorinostat | 2022 |